a global consulting leader in advancing health, wealth and career, and a
wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), has
appointed Jeff Dobro as the US Clinical Services and Innovation Strategy
Leader. In this role he will be responsible for Mercer’s clinical
consulting team and health strategy development. Dr. Dobro will report
to Jean Moore, US Health Specialty and Innovation Leader.
“We are very pleased to welcome Jeff to Mercer,” said Ms. Moore, “He is
one of the most highly regarded strategists and physicians in our
industry and his experience in various healthcare consulting leadership
roles will be a valuable addition to our team as we help clients
strengthen and transform their health benefit and employee well-being
Prior to joining Mercer, Dr. Dobro was the Chief Medical Officer at One
Medical. Before that, he spent six years as the Chief Medical Officer
for RedBrick Health and six years as a consultant at Willis Towers
Watson. Dr. Dobro is a board certified internist and rheumatologist and
an Associate Professor at NYU School of Medicine. He earned his Doctor
of Medicine from Drexel.
delivers advice and technology-driven solutions that help organizations
meet the health, wealth and career needs of a changing workforce.
Mercer’s more than 23,000 employees are based in 44 countries and the
firm operates in over 130 countries. Mercer is a wholly owned subsidiary
& McLennan Companies (NYSE: MMC), the leading global
professional services firm in the areas of risk, strategy and people.
With nearly 65,000 colleagues and annual revenue over $14 billion,
through its market-leading companies including Marsh,
Carpenter and Oliver
Wyman, Marsh & McLennan helps clients navigate an increasingly
dynamic and complex environment. For more information, visit www.mercer.com.
Follow Mercer on Twitter @Mercer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005678/en/